## Abstract Hemophilia is an inherited bleeding disorder caused by a deficiency of functional clotting factors VIII or IX in the blood plasma. The drawbacks of the classical protein substitution therapy fueled interest in alternative treatments by gene therapy. Hemophilia has been recognized as an
Call for risk/benefit study of gene therapy
โ Scribed by Butler, Declan
- Book ID
- 109790682
- Publisher
- Nature Publishing Group
- Year
- 1994
- Tongue
- English
- Weight
- 137 KB
- Volume
- 372
- Category
- Article
- ISSN
- 0028-0836
- DOI
- 10.1038/372716a0
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay or prevent the emergence of drug-resistant mutants. Because drug-resistant mutants are archived and may limit future therapeutic options, prevention is important for long-
Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B